Amarin up 3% following the addition of Vascepa to the SOC Guidelines for Diabetes CV Risk – Amarin Corporation plc (NASDAQ: AMRN)

Amarin (AMRN + 3%) is up slightly following an announcement from the American Diabetes Association that adds vascepa (icosapent ethyl) to its recommendation for therapeutic management to reduce cardiovascular (CV) risk in diabetics with atherosclerotic disease or other triglyceride risk factors and are currently on statin therapy with control of "bad" cholesterol.

The ADA made the change based on the results of the REDUCE-IT study.

It has also updated its guidelines to include the beneficial effects of the product AstraZeneca (AZN -0.7%) Farxiga (dapagliflozin) on reducing the number of hospitalizations for heart failure and progression of chronic renal failure, including an insufficient level of renal function to be able to benefit from treatment (greater than or equal to 45 mL / min, 1.73 m2 greater than or equal to 60 mL / min / 1.73 m2).

The amendments should make it easier for both products to appear on payers' forms.